Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy targeting Parkinson's disease. The company's experimental treatment represents a novel approach using stem cell technology to address the neurodegenerative condition.
The Phase 1/2 trial evaluated the safety and preliminary efficacy of Aspen's stem cell-derived therapy in Parkinson's patients. While specific efficacy metrics and patient population details were not disclosed in the available data, the company characterized the results as positive.